Review of teriflunomide and its potential in the treatment of multiple sclerosis

Clemens Warnke, Gerd Meyer Zu Hörste, Hans Peter Hartung, Olaf Stüve, Bernd C. Kieseier

Research output: Contribution to journalReview article

72 Scopus citations

Abstract

In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.

Original languageEnglish (US)
Pages (from-to)333-340
Number of pages8
JournalNeuropsychiatric Disease and Treatment
Volume5
Issue number1
StatePublished - Nov 24 2009

Keywords

  • Immunosuppressant
  • Multiple sclerosis
  • Oral drugs
  • Teriflunomide

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Review of teriflunomide and its potential in the treatment of multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Warnke, C., Zu Hörste, G. M., Hartung, H. P., Stüve, O., & Kieseier, B. C. (2009). Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatric Disease and Treatment, 5(1), 333-340.